Monopar Therapeutics (MNPR) Operating Expenses (2017 - 2020)

Monopar Therapeutics' Operating Expenses history spans 4 years, with the latest figure at $2.3 million for Q4 2020.

  • For Q4 2020, Operating Expenses rose 84.57% year-over-year to $2.3 million; the TTM value through Dec 2020 reached $6.5 million, up 50.54%, while the annual FY2024 figure was $16.2 million, 83.01% up from the prior year.
  • Operating Expenses for Q4 2020 was $2.3 million at Monopar Therapeutics, up from $1.6 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $14.9 million in Q3 2017 and bottomed at $373839.0 in Q1 2017.
  • The 4-year median for Operating Expenses is $929233.5 (2018), against an average of $1.9 million.
  • The largest YoY upside for Operating Expenses was 140.01% in 2018 against a maximum downside of 95.52% in 2018.
  • A 4-year view of Operating Expenses shows it stood at $736800.0 in 2017, then grew by 25.73% to $926358.0 in 2018, then skyrocketed by 32.23% to $1.2 million in 2019, then surged by 84.57% to $2.3 million in 2020.
  • Per Business Quant, the three most recent readings for MNPR's Operating Expenses are $2.3 million (Q4 2020), $1.6 million (Q3 2020), and $1.5 million (Q2 2020).